UNC13D as A Potential Drug Target for Cancer (G201294)

Target Name: UNC13D

NCBI ID: G201294

UNC13D

UNC13D as A Potential Drug Target for Cancer

UNC13D (HPLH3), also known as human platelet-derivedless hybridoma 3, is a protein that is expressed in the placenta and has been shown to play a role in the development and maintenance of cancer. It is a type of cancer stem cell, which are cells that have the ability to give rise to all different types of cancer.

One of the things that makes UNC13D so interesting as a potential drug target is its ability to interact with a protein called PDGF-BB. PDGF-BB is a protein that is produced by platelets, and it has been shown to play a role in the development and progression of many types of cancer.

Research has also shown that UNC13D is involved in the regulation of the blood supply to the tumor, which can make it an attractive target for a drug that can disrupt the blood supply to the cancer cells.

Another potential mechanism by which UNC13D may be involved in the development and progression of cancer is its role in the regulation of cell signaling pathways. It has been shown to play a role in the regulation of several different signaling pathways, including the TGF-β pathway and the Wnt pathway.

These signaling pathways are involved in the regulation of cell growth, differentiation, and survival, and have been implicated in the development and progression of many types of cancer. By targeting UNC13D with a drug that can disrupt these signaling pathways, researchers may be able to inhibit the growth and spread of cancer cells.

Another potential mechanism by which UNC13D may be involved in the development and progression of cancer is its role in the regulation of the immune system. It has been shown to play a role in the regulation of the immune response, which is important for the immune system's ability to detect and destroy cancer cells.

Research has also shown that UNC13D is involved in the regulation of the angiogenesis, which is the process by which new blood vessels are formed. This may be an attractive target for a drug that can disrupt the formation of new blood vessels, which can contribute to the development and progression of cancer.

In conclusion, UNC13D is a protein that has been shown to play a role in the development and progression of cancer. Its ability to interact with PDGF-BB and regulate cell signaling pathways, as well as its role in the regulation of the immune system and angiogenesis, makes it an attractive potential drug target. Further research is needed to fully understand the mechanisms by which UNC13D functions and to develop effective treatments for cancer.

Protein Name: Unc-13 Homolog D

Functions: Plays a role in cytotoxic granule exocytosis in lymphocytes. Required for both granule maturation and granule docking and priming at the immunologic synapse. Regulates assembly of recycling and late endosomal structures, leading to the formation of an endosomal exocytic compartment that fuses with perforin-containing granules at the immunologic synapse and licences them for exocytosis. Regulates Ca(2+)-dependent secretory lysosome exocytosis in mast cells

The "UNC13D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UNC13D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets